Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239118 | 1.00 | RAB9A (0.50) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL8249411 | 1.00 | RAB9A (0.50) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL131112 | 0.99 | RAB9A (0.49) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4585660 | 0.99 | RAB9A (0.49) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7951153 | 0.91 | NPC1 (0.51) | RAB9ANPC1KMT2AALDH1A1KDM4E | |
| SCHEMBL5720838 | 0.90 | GAA (0.47) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL5720890 | 0.88 | KMT2A (0.48) | RAB9ANPC1KMT2AALDH1A1KDM4E | |
| SCHEMBL28885836 | 0.87 | PRKCI (0.46) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL28885837 | 0.87 | PRKCI (0.46) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL15238894 | 0.86 | KMT2A (0.55) | RAB9AKMT2AKDM4EMAPK9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1079825-B1 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | UBE INDUSTRIES, LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1079825-A4 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6344456-B1 | ANTICOAGULANTS | LABORATOIRE L. LAFON (FR) | 2002-02-05 | — | — | US | disclosed |
| US-6262084-B1 | Compounds that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1079825-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999052493-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| US-5378727-A | ADMINISTERING TO MAMMALS | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | RAB9A 1000/4885NPC1 1077/4885CYP3A4 1942/4885 |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | ALAD, ARSA, ALDH7A1 | RAB9A 652/4885NPC1 2597/4885CYP3A4 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.